Inclusion Criteria:

1. Have histologically confirmed adenocarcinoma of the prostate, with clinically
significant bone metastases exhibiting castrate-resistant progression. Progression is
defined as any of the following: 1) New lesions or obviously worsening lesions on
bone scan within the previous three months; 2) a PSA doubling time of < 3 months; 3)
New or progressive symptoms requiring a change in therapy that are referable to the
cancer; 4) New extra-osseous lesions within the past 3 months

2. Have progression in the face of a serum testosterone of less than 50 ng/dL, and have
either failed or refused chemotherapy

3. Have an Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

4. Have adequate bone marrow function defined as an absolute peripheral granulocyte
count of >/= 1,000/mm^3 and platelet count of >/= 140,000/mm^3; hemoglobin >/= 9.0
g/dL (without transfusion or growth factor support), unless the patient is < 6 weeks
from last cancer therapy in which case transfusion is allowed.

5. Have adequate hepatic function defined as a total bilirubin of
6. Have adequate renal function defined as serum creatinine normal or creatinine clearance >/= 60 mL/min (measured or calculated). In the absence
of hematuria, patients must have either a negative urinalysis for protein (i.e. no
more than "trace" by dipstick) or a 24 hour urine collection showing less than 1,000
mg of protein/24 hour. In the presence of hematuria, patients may have up to 2,000 mg
of protein/24 hour.

7. Have adequate cardiovascular function as defined by: i) a normal beta-natruetic
peptide (BNP) with ii) no signs or symptoms suggestive of cardiac disease and iii) a
normal Electrocardiography (ECG). Alternatively, patient not meeting all of these
criteria is still eligible if he has both i) an echocardiogram showing an ejection
fraction (EF) of 45% or greater (and no more than "mild" diastolic dysfunction) and
ii) a Brain Natriuretic Peptide (BNP)of < 200

8. Sign the current IRB approved informed consent indicating that they are aware of the
investigational nature of this study, in keeping with the policies of the institution

9. Age >/= 18 years old

Exclusion Criteria:

1. Small cell prostate cancer

2. Infectious process, which, in the opinion of the investigator, could worsen or its
outcome be affected, as a result of the investigational therapy

3. Any of the following in previous 6 months: New York Heart Association (NYHA) Class
III/IV congestive heart failure, unstable angina, cerebrovascular accident (including
transient ischemic attack), pulmonary embolism or myocardial infarction (by ECG or
serologic criteria)

4. Significant co-morbidity that could affect the safety or evaluability of
participants, including: a) Chronically uncontrolled hypertension, defined
conventionally as consistent systolic pressures above 140 or diastolic pressures
above 90 despite therapy. Note that this is NOT a criterion related to particular BP
results at the time of assessment for eligibility, nor does it apply to acute BP
excursions that are related to iatrogenic causes, acute pain or other transient,
reversible causes. (Please see further explanation in the Treatment Plan below)

5. (# 4 cont'd) b) uncontrolled diabetes mellitus (defined as Hgb A1c > 8.5, or
symptomatic hypoglycemic episodes > 1 per week during the two months prior to
eligibility evaluation, or more than 1 glucose excursion to >300 mg/dL in prior two
months--unless clearly iatrogenic and the cause has been eliminated),c) lung disease
requiring supplemental oxygen, d) known chronic liver disease, or e) HIV infection

6. Hydronephrosis (either bilateral or involving a solitary kidney) that has not been
addressed by means of a nephrostomy or indwelling stent. (Non-obstructive
hydronephrosis in setting of prior urinary diversion is allowed.)

7. Overt psychosis, mental disability or being otherwise incompetent to grant informed
consent or a history of non-compliance with medical care

8. Patients must not require ongoing therapy with non-steroidal anti-inflammatories
(NSAIDs),other than low-dose (i.e. 81 mg or less) aspirin daily, i.v. vancomycin,
aminoglycosides, or other potently nephrotoxic drugs, and must agree to abstain from
NSAIDs for the duration of their participation in the trial

9. Any other medical condition that in the opinion of the principal investigator would
compromise the ability to deliver or evaluate study drug

10. Unwillingness to maintain adequate contraception measures for the entire course of
the study

11. Any therapy for prostate cancer (other than ongoing androgen deprivation or
associated hormonal therapies such as diethylstilbesterol, low-dose dexamethasone,
megace, etc) in the two weeks prior to starting BMTP-11